An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Progression Free Survival (PFS) Per Modified World Health Organization (mWHO) Criteria

PFS per mWHO was defined as the time between the randomization date and the time of disease progression per mWHO criteria or death, whichever occurred first and was measured in months. mWHO criteria: New lesions always mean progression; Changes in non-measurable lesions contribute in the definitions of Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD).

Time frame: Randomization up to 91 irPFS events (Approximately 19 months )

Overall Survival (OS) at Primary Endpoint

OS was defined as the time from the date of randomization until the date of death. For those participants who have not died, OS was censored on the last date the participant was known to be alive.

Time frame: Randomization up to 91 irPFS events (Approximately 19 months)

Overall Survival (OS) at Study Completion

OS was defined as the time from the date of randomization until the date of death. For those participants who have not died, OS was censored on the last date the participant was known to be alive.

Time frame: Randomization up to end of study, April 2015 (Approximately 28 months)